Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Civitas Therapeutics Inc.

Division of Acorda Therapeutics Inc.

Latest From Mylan Technologies Inc.

Cure Therapeutics Inc.

Cure Therapeutics hopes to help the millions of athletes and workers who suffer from tendonitis. The company is developing transdermally delivered nitric oxide drugs designed to lessen the pain and speed recovery from chronic musculoskeletal conditions like swimmer's shoulder, tennis elbow, jumper's knee, and Achilles tendonitis.
BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (2/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Mylan's New Focus

For most of the 1990s, Mylan Laboratories was the dominant US generics manufacturer both in terms of financial performance and creative competitive strategies. But it seems to have lost its way a bit and is struggling to regain its competitive edge in an industry that no longer reflects the world it grew up in. Revenues grew a sluggish 7% to $846 million in 2001, in part because efforts to diversify into proprietary drugs haven't met goals. In June, two top executives left, both of whom had been there only a short time.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Corregidor Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Acorda Therapeutics Inc.
  • Senior Management
  • Mark Iwicki, Pres. & CEO
    Peter Courossi, CFO
    Richard Batycky, PhD, CSO
    Bryan E Stuart, CBO
  • Contact Info
  • Civitas Therapeutics Inc.
    Phone: (617) 660-4110
    190 Everett Ave.
    Chelsea, MA 02150